A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
Status:
Terminated
Trial end date:
2018-10-03
Target enrollment:
Participant gender:
Summary
This study will examine the effectiveness and safety of glembatumumab vedotin as monotherapy
or in combination with immunotherapies in patients with advanced melanoma.